Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])

Authors

Daniel Hanggi, University of Heidelberg
Nima Etminan, University of Heidelberg
Francois Aldrich, University of Maryland - Baltimore
Hans Jakob Steiger, Heinrich-Heine-University
Stephen A. Mayer, Mount Sinai Hospital
Michael N. Diringer, Washington University School of Medicine in St. Louis
Brian L. Hoh, University of Florida
J Mocco, Mount Sinai Hospital
Herbert J. Faleck, Edge Therapeutics
R. Loch Macdonald, University of Toronto
Newton Investigators

Journal

Stroke

Publication Date

2017

Volume

48

Issue

1

Inclusive Pages

145-151

Document Type

Open Access Publication

DOI

10.1161/STROKEAHA.116.014250

Rights and Permissions

Hanggi D, Etminan N, Aldrich F, Steiger HJ, Mayer SA, Diringer MN, Hoh BL, Mocco J, Faleck HJ, Macdonald RL, NEWTON Investigators (2017) Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]). Stroke, 48(1): 145-151. doi: 10.1161/STROKEAHA.116.014250. © 2016 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDervis License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Recommended Citation

Hanggi, Daniel; Etminan, Nima; Aldrich, Francois; Steiger, Hans Jakob; Mayer, Stephen A.; Diringer, Michael N.; Hoh, Brian L.; Mocco, J; Faleck, Herbert J.; Macdonald, R. Loch; and Newton Investigators, "Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])." Stroke. 48, 1. 145-151. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5888